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Abstract
Background: Abrogation of apoptosis for prolonged cell survival is essential in cancer progression. In our previous studies,
we showed the MMP-2 downregulation induced apoptosis in cancer cell lines. Here, we attempt to investigate the exact
molecular mechanism of how MMP-2 depletion leads to apoptosis in glioma xenograft cell lines.
Methodology/Principal Findings: MMP-2 transcriptional suppression by MMP-2siRNA (pM) induces apoptosis associated
with PARP, caspase-8 and -3 cleavage in human glioma xenograft cells 4910 and 5310. Western blotting and cytokine array
showed significant decrease in the cellular and secreted levels of TNF-a with concomitant reduction in TNFR1, TRADD,
TRAF2, RIP, IKKb and pIkBa expression levels resulting in inhibition of p65 phosphorylation and nuclear translocation in pM-
treated cells when compared to mock and pSV controls. In addition MMP-2 suppression led to elevated Fas-L, Fas and FADD
expression levels along with increased p38 and JNK phosphorylation. The JNK-activity assay showed prolonged JNK
activation in pM-transfected cells. Specific inhibition of p38 with SB203580 did not show any effect whereas inhibition of
JNK phosphorylation with SP600125 notably reversed pM-induced cleavage of PARP, caspase-8 and -3, demonstrating a
significant role of JNK in pM-induced cell death. Supplementation of rhMMP-2 counteracted the effect of pM by remarkably
elevating TNF-a, TRADD, IKKb and pIkBa expression and decreasing FADD, Fas-L, and phospho-JNK levels. The EMSA
analysis indicated significant reversal of pM-inhibited NF-kB activity by rhMMP-2 treatment which rescued cells from pM-
induced cell death. In vivo studies indicated that pM treatment diminished intracranial tumor growth and the immuno
histochemical analysis showed decreased phospho-p65 and enhanced phospho-JNK levels that correlated with increased
TUNEL-positive apoptotic cells in pM-treated tumor sections.
Conclusion/Significance: In summary, our study implies a role of MMP-2 in the regulation of TNF-a mediated constitutive
NF-kB activation and Fas-mediated JNK mediated apoptosis in glioma xenograft cells in vitro and in vivo.
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Introduction
Despite recent advances in treatment strategies, glioblastomas
(GBM) are the most aggressive and deadliest form of primary
brain tumors. These tumors remain incurable, and patients have a
mean survival of 12 months after diagnosis [1]. Many factors
support the highly treatment-resistant and persistent nature of
GBM. Genetic abnormalities can defend the tumor from
conventional therapies, the blood-brain barrier limits the entry
of chemotherapeutic agents to tumors, and GBM have highly
invasive potential with increased extracellular matrix (ECM)
disruption [2–4]. The ECM disruption is achieved in part by the
action of a group of serine-, cysteine- and metallo-proteases,
among which matrix metalloproteases (MMPs), are zinc-depen-
dent endopeptidases involved in the inclination of tumor cells to
overrun normal tissues and to metastasize to distant sites [5,6].
Among MMP family members, MMP-2 contains fibronectin
domains for collagen binding and preferentially degrades base-
ment membrane components such as type-IV collagen, which
ultimately regulate cell migration and proliferation during tumor
invasion [6]. The expression and activities of MMPs are increased
in almost all human malignancies and are associated with
advanced metastatic tumor stage and poor survival [7].
RNA interference (RNAi) is accomplished by different classes of
small RNAs including microRNAs (miRNAs), small interfering
RNAs (siRNAs) and Piwi-interacting RNAs (piRNAs) [8]. Among
these, siRNAs which are short stretches of double-stranded RNA
molecules are employed in specific knockdown of desired genes
thus being widely used to investigate gene function with a future
potential as therapeutic agents in the treatment of various diseases
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targeted silencing of the MMP-2 gene using siRNA, and molecular
mechanism in relation to apoptotic cell death of glioma both in vitro
and in vivo.
The pro-inflammatory cytokine tumor necrosis factor-a (TNF-a)
regulates various signaling pathways in proliferation, apoptosis, and
inflammation through the activation of phospholipases, mitogen-
activated protein kinases and NF-kB [10,11]. The pleotropic
biological functions of TNF-a are mediated through its cognate
receptors TNFR1 and TNFR2, which activate various signalling
pathways predominantly through TNFR1 [12]. The adaptor
protein TRADD recruits additional adaptor proteins such as
TRAF2, FADD and RIP [10,13]. The TNF-a mediated functions
emanate from TRADD, which transduces signals to different
effectors such as IkB kinase (IKK), Janus N-terminal Kinase (JNK)
and caspases [10]. The distinct role of TRADD in proliferation and
apoptosis through binding with TRAF2 and FADD has been
previously elucidated. TRADD directly interacts with TRAF2 at its
N-terminal region, and this interaction is essential for cell survival
through NF-kB signaling and efficient inhibition of apoptosis [12].
Activation of NF-kB through inhibitory phosphorylation of IkBb y
IKK complex leads to the nuclear translocation of NF-kB, where it
stimulates the transcription of target genes that are involved in
immune responses, inflammation and cell survival [14,15]. It has
been demonstrated that NF-kB controls the expression of various
anti-apoptotic proteins including XIAP, IAP and gadd45a which
inhibit caspase-dependent apoptosis and also encode target genes
that inhibit c-Jun N-terminal kinase (JNK) activation [16–19]. On
the other hand, Fas (APO-1/CD95) is a cell surface death receptor
and upon Fas-ligand binding and activation, the procaspase-8 is
recruited onto the Fas complex through FADD [20]. Cleavage and
activation of pro caspase-8 induces activation of effector caspases-3
and -7 as well as Bid, which initiates the apoptotic machinery. The
receptor interacting protein (RIP) is a kinase recruited to TNFR1-
TRADD complex essential for activation of NF-kB signalling and
the downregulation and cleavage of RIP from TNFR1 complex
leads to inhibition in NF-kB activation and induces apoptosis
[21–23].
The mitogen activated protein kinase (MAPK) family has three
components: extracellular signal regulated kinase cascade, JNK
cascade and p38 MAPK cascade. The c-Jun N-terminal kinase
(JNK) is a serine/threonine protein kinase activated by a variety of
extracellular stimuli such as UV and ionizing radiation, heat
shock, inflammatory cytokines, metabolic inhibitors and osmotic
or redox shock leading to cell death [24]. JNK is involved in
several forms of cell-specific and stress-induced apoptosis, which
are dependent on cell type and stimulus. It phosphorylates serine
63 and 73 at the N-terminal domain of c-Jun, thus activating the
transcriptional activity of AP-1 [25]. The inhibition of NF-kB
activation is required for prolonged JNK activation, which
simultaneously results in apoptosis [16,25,26]. Several studies
showed the role of JNK activation in the accomplishment of Fas
signaling induced cell death [27–29].
Our previous studies with MMP-2 downregulation activated
TIMP-3 induced Fas/CD95 mediated extrinsic apoptotic pathway
and enhanced radiosensitivity in lung adenocarcinoma cells [30–
32]. Our studies also indicated the siRNA mediated MMP-2
downregulation led to apoptosis in human glioma xenograft cells
[32]. In the current study, we provide further insights in to the
molecular mechanism underlying siRNA mediated MMP-2
depletion-induced apoptosis in human glioma xenograft cells
4910 and 5310 both in vitro and in vivo. We observed that the
transcriptional suppression of MMP-2 inhibited TNF-a induced
IKKb/pIkBa mediated NF-kB activation by decreasing TRADD-
TRAF2 interactions in xenograft cell lines. Here, we report
concomitant activation MAP kinases, JNK and p38 and a role of
JNK activation but not p38 in MMP-2siRNA induced apoptosis.
Results
MMP-2siRNA (pM) downregulates MMP-2 expression and
activity in 4910 and 5310 cells
We transfected 4910 and 5310 cells with CMV promoter-driven
MMP-2siRNA in pcDNA3.0 (pM) and determined the levels of
MMP-2 using gelatin zymography, Western blotting, RT-PCR
and immunofluorescence analyses. Conditioned media from pM-
treated cells showed reduced gelatinase activity in comparison to
mock and pSV-treated 4910 and 5310 cells (69.162.5% and
68.662.4%, respectively) (Fig. 1A). We observed substantial
decrease in the MMP-2 expression up to 70.262.6% and
69.463.3% in pM-treated 4910 and 5310 cells as compared to
mock and pSV treatments by Western blotting (Fig. 1B).
Transcriptional levels of MMP-2, as assessed by RT-PCR,
confirmed the decreased expression levels of MMP-2 up to
68.263.0% in pM-transfected 4910 cells and 69.062.2% in pM-
transfected 5910 cells as compared to mock and pSV-treated
counterparts (Fig. 1C). Quantification of relative expression level
and gelatinolytic activity of MMP-2 showed significant decrease
upon pM treatment at p,0.01. Immunofluorescence studies
showed high expression levels of MMP-2 in mock- and pSV-
treated 4910 and 5310 cells (Fig. 1D). The quantification of
relative fluorescence intensity indicated a significant decrease in
the MMP-2 expression upon pM treatment at 72 h (p,0.01).
MMP-2 downregulation leads to impeded proliferation
and induces apoptosis in vitro
We next assessed the effect of pM on cell viability of 4910 and
5310 cells at different time intervals (24–96 h) using the MTT
assay. We observed a time-dependent loss of cell viability
significantly at 72 h of up to 61.464.2% in 4910 cells and
62.062.4% in 5310 cells (p,0.01). This effect was very prominent
at 96 h with a significant loss of cell viability of up to 74.562.5%
and 75.063.2% in 4910 and 5310 cells respectively, at p,0.01
(Fig. 2A). The FACS analysis to estimate the percent of apoptotic
cells in the sub-G1 phase at the end of 72 h treatment revealed a
remarkable cell death induced by pM. The percent of sub-G1 cells
in pM-treated 4910 and 5310 cells was 32.861.2% and
33.961.8% respectively; whereas mock-treated cells only had
7.160.2% and 6.860.3% apoptotic cells and pSV-treated cells
displayed a cell death rate of 6.760.3% and 7.460.15% (Fig. 2B).
Analysis of DNA content indicated an increased proportion of cells
in the G2-M phase after pM treatment. This could be due to cell
cycle block in the G2-M phase or preferential apoptosis of these
cells in late S and G2-M. Subsequently, to verify that this cell death
was a result of apoptosis and to determine the mediators involved,
we subjected whole cell lysates to Western blotting and determined
cleavage of PARP, caspase-8 and caspase-3. These results clearly
showed increased cleavage of PARP, caspase-8 and caspase-3 in
the pM-treated cells when compared to the mock and pSV-treated
controls, thereby implying that there is a significant hike in
apoptotic cell death upon downregulation of MMP-2 in both of
these cell lines (Fig. 2C). In addition, to confirm the apoptosis
secondary to MMP-2 downregulation we determined extent of
DNA fragmentation at 72 h post-transfection by TUNEL assay. In
TUNEL assay, the apoptotic cells were significantly higher in pM-
transfected cells when compared to mock and pSV treatments
(Fig. 2D). The number of apoptotic cells were counted at 72 h
post-transfection and percentage of TUNEL positive apoptotic
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56.865.0% of the pM-transfected 4910 and 5310 cells were
TUNEL-positive as compared to that of mock-treated (3.260.5%
and 3.060.1%) and pSV-treated (3.360.36% and 2.860.5) cells,
respectively. These results suggest that pM induced caspase-
dependent apoptotic cell death.
pM leads to decreased TNF-a expression and inhibits p65
phosphorylation and nuclear translocation via hindrance
of IKKb and phosphorylation of IkBa
The cytokine antibody array was performed using conditioned
media to check the possible modulation of various cytokine levels in
MMP-2siRNA treatments (data not shown). Among these we
Figure 1. Effect of RNA interference on MMP-2 expression in human xenograft cell lines 4910 and 5310. Different treatments included
control (mock), pSV (scrambled vector), pM (pMMP-2Si, pcDNA3.1 vector containing siRNA sequence for MMP-2). A. Gelatin zymography of
extracellularly secreted MMP-2 in to tumor conditioned medium at 72 h post-transfection. The bar diagrams below represent the quantification of
gelatinolytic band intensities in 4910 and 5310 cells with mean6SE of at least three individual experiments. B. Western blotting showing protein
expression levels in mock, pSV and pM treatments. At 72 h post-transfection, cells were harvested and whole cell lysates were prepared using RIPA
buffer. The representative blot of three different repetitions is shown. The blot was stripped and re-probed with anti-GAPDH antibody, which served
as a loading control. The following bar diagram shows relative expression levels of MMP-2 protein with different treatments. C. Semiquantitative RT-
PCR shows transcriptional levels of the MMP-2 gene and GAPDH was as a loading control. Band intensities were quantified using ImageJ 1.42
software (NIH Bethesda, USA) and the arbitrary units were plotted using mean6SE of at least three individual repetitions. D. Immunofluorescence
study using blinded analysis showing the expression of MMP-2 in mock, pSV- and pM-treated 4910 and 5310 cells at 72 h post-transfection. After the
treatments, cells were fixed in 4% paraformaldehyde, incubated with anti-MMP-2 antibody followed by Alexa FluorH secondary antibodies, and
observed under confocal microscopy. DAPI was used for nuclear counterstaining. Cells in randomly selected microscopic fields in three individual
repetitions were represented where the fluorescence intensity was quantified using ImageJ and the arbitrary fluorescence units were plotted as
mean6SE. The significant difference among different treatments in above experiments was represented by ‘‘**’’, at p,0.01.
doi:10.1371/journal.pone.0019341.g001
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conditioned medium when compared to conditioned medium in
pSV treatment. Densitometric analysis showed up to ,3 fold
decreases in TNF-a levels upon MMP-2 depletion in both 4910 and
5310 cells. Western blotting using whole cell lysates confirmed the
significant decrease of TNF-a expression in pM treated cells
(Fig. 3A). With the prominent decrease in TNF-a expression, we
next proceeded to determine the p65 phosphorylation levels in the
cytosolic and nuclear fractions. There was drastic reduction in the
phosphorylated p65 in the nuclear fractions of pM-treated cells
when compared to either mock or pSV counterparts (Fig. 3B). The
cytosolic phopsho-p65 levels also displayed remarkable decrease
indicating that overall phosphorylation and subsequent nuclear
translocation were inhibited in the pM-treated cells. To confirm
Figure 2. MMP-2 RNA interference inhibited proliferation and induced apoptosis in human xenograft cell lines. A. 4910 and 5310 cells
were treated with mock, pSV and pM for different time points (24 h, 48 h, 72 h and 96 h) and subjected to MTT cell viability assay. Data were
represented as mean6SE of three independent experiments. The significant difference among different treatments was represented by ‘‘*’’, at
p#0.05 and ‘‘**’’, at p,0.01. B. Cell cycle distribution in 4910 and 5310 cells 72 h after mock, pSV and pM treatments. DNA content was analyzed by
flow cytometry as described in Materials and Methods. The percentage of apoptotic population in cells was represented as G0 in histograms. Three
individual experiments were conducted to confirm similar results. C. Whole cell lysates were prepared from mock, pSV- and pM-treated cells and
subjected to Western blotting to check the cleavage of PARP, caspases-8 and caspases-3. Blots are representative of 3 independent experiments. D.
Xenograft cell lines 4910 and 5310 were seeded in chamber slides and transfected with pSV and pM after 24 h for 72 hours at the end of which the
cells were fixed in 4% paraformaldehyde and subjected to TUNEL assay. E. Percentage of apoptotic cells was plotted in corresponding bar diagrams
with values representing mean6SE. and significant difference among treatments is represented by ‘‘**’’, p,0.01.
doi:10.1371/journal.pone.0019341.g002
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microscopy. In mock and pSV-treatments a higher phosphorylation
levels of p65 were observed with the majority of staining resided in
the nuclei indicating constitutive NF-kB activation in these cells.
While the pM-treated cells showed significant loss of phospho-p65
with very little or no nuclear expression (Fig. 3C). Even though the
inhibition in phosphorylation and nuclear translocation of p65 was
evident at 24 h and 48 h post-transfection the inhibition was more
prominent at the end of 72 h (data not shown). These results with
evident inhibition of nuclear localization of p65 indicate that the
MMP-2 depletion leads to a possible upstream change in NF-kB
activating stimulus, which in turn, causes inhibition of its activation.
The activation and nuclear translocation of NF-kB requires
phosphorylation, ubiquitination and proteolytic degradation of
IkBa by IKKb. To determine the effect of pM on the
phosphorylation of IkBa, we next determined the expression
levels of IKKb and total & phosphorylated IkBa levels using whole
cell lysates. MMP-2 downregulation led to significant decrease in
the IKKb with simultaneous reduction in the expression levels of
phosphorylated IkBa and elevation in total IkBa in both 4910 and
5310 cell lines (Fig. 3D). These results provide convincing evidence
about the significant inhibitory effect of pM on the IKKb-induced
phosphorylation and degradation of IkBa and gives possible
explanation for inhibited nuclear translocation of NF-kB through
the IKKb-IkBa pathway upon MMP-2 downregulation.
Modulation of TRADD, TRAF2, FADD, Fas-L and Fas
expression levels in pM treated cells
Further, to study the essential upstream events in the IKKb-
IkBa mediated NF-kB pathway involving intermediate adaptor
proteins such as TRADD, RIP and TRAF-2, we next examined
their expression levels and interaction using co-immunoprecipita-
tion studies. We observed a significant decrease in the expression
levels of TNFR1, TRADD, TRAF2 and RIP in pM-treated 4910
and 5310 cells. The FADD binds to activated Fas/Fas-L and
facilitates recruitment of and activation of pro-casapse-8 leading to
MAP kinase mediated cell death [20]. The Fas, Fas-L and FADD
expression levels were remarkably elevated in pM-treated cells
when compared to the controls suggesting a possible role of Fas
signaling in pM-induced caspase-mediated cell death in these cells
(Fig. 4A). The binding of TRADD and TRAF2 was decreased, as
evident in the immunoprecipitation studies suggesting an inhibi-
tion in recruitment of TRAF2 to TRADD and giving a possible
explanation for the inhibition of TRADD-TRAF2-mediated NF-
kB activation in pM-treated cells (Fig. 4B). To further check the
inhibitory role of MMP-2siRNA in TNF-a induced NF-kB
activation, TNF-a was added to the culture medium to pM-
transfected cells. The TNF-a treatment alone remarkably
increased the p65 phosphorylation when compared to mock or
pSV treated controls (Fig. 4C). On the other hand, the
combination pM+TNF-a showed significant decrease in phop-
sho-p65 when compared to TNF-a treatment alone implying the
role of TNF-a in MMP-2siRNA-inhibited p65 activation (Fig. 4D).
pM activates the MAP kinases p38 and JNK
To assess the expression levels of the MAP kinases after MMP-2
depletion, whole cell lysates were prepared at 24, 48 and 72 h post-
transfection with pM and subjected to Western blotting. We
observed dramatic increases in phosphorylated JNK and p38 levels
after treatment with pM as compared to mock and pSV treatments
in both 4910 and 5310 cells. We recorded a significant time-
dependent prolonged activation of JNK of up to 72 h after
transfection with up to11-foldincreaseinphospho-JNK and upto 5
fold increase in phospho-p38; there was no change in expression of
total JNK or p38 (Fig. 5A). The prolonged activation of JNK
subsequently resulted in the elevation of phosphorylation of c-Jun.
The simultaneous elevation in phospho-JNK and phospho-p38
MAPK and enhancedapoptoticresponseintransfectedcellssuggest
a possible role of these molecules in pM-mediated cell death.
JNK inhibitor, but not p38 inhibitor, reverses pM-induced
cell death
Sequentially, to investigate the possible involvement of en-
hanced phospho-JNK and phospho-p38 in pM-induced cell death,
we performed combination treatments of mock, pSV and pM with
JNK inhibitor II (SP600125) or p38 MAPK inhibitor (SB203580)
as described previously. Cell viability in individual experiments
was determined to assess the reversal of pM-induced cell death by
these inhibitors. In the combination treatment of pM+SB203580
there was no significant reversal of loss of cell viability with
SB203580 treatment, which indicates that there was no obvious
role of enhanced p38 MAPK phosphorylation in pM-induced
apoptosis (Fig. 5B). However, JNK phosphorylation inhibition by
SP600125 supplementation to pM treatment remarkably in-
creased cell viability by blocking pM-induced cell death in both
4910 (from pM; 36.662.8 to pM+SP600125; 61.561.5%) and
5310 (from pM; 35.562.0 to pM+SP600125; 62.663.3%) cells
(p,0.05). While, the supplementation of either SB203580 or
SP600125 on mock and pSV treatments showed similar response
on cell viability as that of mock and pSV suggesting that the
addition SP203580 has no or little effect on cell death. These
results clearly indicate an apparent role of JNK activation in pM-
mediated cell death. With the elevated and prolonged phosphor-
ylation of JNK, we next proceeded to determine JNK activity
using c-Jun fusion protein coated beads after pM treatments. We
noted a gradual, time-dependent significant increase in JNK
activity as observed by enhanced c-Jun phosphorylation, which
resulted in increasing phosphorylation of c-Jun in both cell lines
upon MMP-2 depletion from 24 to 72 h (Fig. 5C). The mock and
pSV treatments did not show any time dependent elevation of
JNK activity (data not shown). We next assessed the affect of
enhanced p38 and JNK phosphorylation on pM induced cell
death through combination experiments mock, pSV and pM in
conjunction with SP600125 and SB203580 by subjecting whole
cell lysates to Western blot analyses for identifying the cleavage of
apoptotic molecules. In corroboration with the cell viability assays,
Western blotting clearly indicated that the enhanced cleavage of
PARP, caspase-8, and caspase-3 by treatment with pM alone was
compromised in these cells when treated with SP600125,
suggesting a significant reversal of cleavage of apoptotic molecules
in combination of pM+SP600125. However, treatment with
SP600125 alone led to decreased caspase cleavage as compared
to mock treatments, implying blocking of prolonged JNK
phosphorylation in pM-treated cells protects these cells from
JNK-induced cell death (Fig. 5D). On the other hand, treatment
with p38 inhibitor SB203580 along with pM did not significantly
reversed the pM-induced cell death which is evident from the
cleavage of apoptotic molecules in combination treatment
comparable to the pM treatment alone. The treatments with
either SP600125 or SB203580 alone did not show any effect on
phospho-p38 and phospho-JNK respectively (Fig. 5D).
Supplementation of rhMMP-2 rescued 4910 and 5310
cells from pro-apoptotic effect of pM and reversed the
inhibited NF-kB DNA binding activity
To further confirm that the observed apoptosis in our
experiments was caused by specific downregulation of MMP-2
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with recombinant human MMP-2 (rhMMP-2). We observed a
significant dose-dependent elevation in MMP-2 expression in both
4910 and 5310 cells when rhMMP-2 was added into the medium.
We chose an optimized concentration of 25 ng/ml rhMMP-2 for
combination treatments (data not shown). The reversal of MMP-2
downregulation and subsequent apoptosis upon the addition of
rhMMP-2 was confirmed by Western blotting. MMP-2 expression
hampered by pM treatment was overturned upon supplementa-
tion of rhMMP-2 in both 4910 and 5310 cells. As noted earlier,
pM induced cleavage of PARP, caspase-8 and caspase-3; this
cleavage was reduced in rhMMP-2-treated cells as compared to
either mock or pSV-treated cells. The combination treatment of
pM+rhMMP-2 reversed the PARP, caspase-8 and -3 confirming
the pro-apoptotic function of pM treatment in both cell lines
(Fig. 6A). The relative intensities of cleaved caspase-8 and caspase-
3 were quantified and plotted in the bar diagram which clearly
showed the significant reversal of elevated caspase cleavage in the
combination treatment (Fig. 6B). Western blotting showed
elevated expression of TNF-a and TRADD in the rhMMP-2
treated cells and the inhibition of these molecules by pM treatment
alone was significantly reversed in the combination treatment. The
IKKb and pIkBa were subsequently elevated in rhMMP-2
treatment and a significant reversal in the combination of
pM+rhMMP-2 (Fig. 6C). Similarly, the treatment of pM with
augmentation of rhMMP-2 restored the nuclear expression levels
of phospho-p65 in pM-treated 4910 and 5310 cells, whereas
rhMMP-2 alone significantly enhanced the nuclear levels of
phospho-p65 (Fig. 6D). In addition, to determine the effect of these
treatments on NF-kB DNA binding activity nuclear extracts from
Figure 3. MMP-2siRNA induced inhibition of TNF-a mediated phosphorylation and nuclear translocation of p65 subunit of NF-kBi n
4910 and 5310 xenograft cell lines. A. The 4910 and 5310 cells were transfected with either pSV or pM for 72 h as described in Materials and
Methods. Conditioned medium (CM) was collected and subjected to cytokine array following manufacturer’s instructions. The positive (Pos) and
negative (Neg) controls show biotin-conjugated and non-biotinylated IgG respectively on the array. The tumor necrosis factor-alpha (TNF-a) levels in
pSV (Scrambled Vector) control and pM (MMP-2siRNA) treatments were compared and relative intensity was estimated by densitometric analysis
using ImageJ 1.42 (NIH). The arithmetic mean6SE values obtained from two independent repetitions were plotted in the bar diagram and
significance was represented by ‘‘**’’, at p,0.01. Whole cell lysates subjected to Western blotting to check the TNF-a expression levels. B. Cytoplasmic
and nuclear extracts were subjected to Western blotting where HDAC-1 and GAPDH were used as internal controls for nuclear and cytosolic fractions,
respectively. C. Immunocytochemistry showing the expression levels of phospho-p65 in mock, pSV and pM treated 4910 and 5310 cells. Cells were
fixed in paraformaldehyde and incubated with anti-phospho-p65 antibody followed by Alexa FluorH anti-rabbit secondary antibody, mounted and
the expression levels and cellular localization of phospho-p65 were captured under a confocal microscope. The nucleus was counterstained with
DAPI. D. The expression levels of IKKb,I kBa, and pIkBa were determined in the whole cell lysates from mock, pSV- and pM-treated cells at 72 h post-
transfection. Blots are representative of three independent experiments where GAPDH served as loading control.
doi:10.1371/journal.pone.0019341.g003
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pM+rhMMP-2 were used to perform EMSA. The results in
Figure 6E clearly show that pM significantly reduced DNA-
binding activity when compared to mock and pSV-treated 4910
and 5310 cell lines while rhMMP-2 treatment alone enhanced
DNA binding activity. Moreover, supplementation rhMMP-2 to
pM-treated cells restored the pM-inhibited NF-kB DNA binding
activity (Fig. 6E). We carried out the TUNEL assay to further
check the possible reversal of pM-induced apoptotic cell death by
either SP600125 or rhMMP-2. These clearly indicated a
significant reversal of pM-induced cell death by the treatment
with either SP600125 or rhMMP-2 in both cell lines (Fig. S1). The
percentage of apoptotic cells was plotted which showed a
significant reversal pM-induced cell death by SP600125 and
rhMMP-2 while the treatment with SP600125 and rhMMP-2
showed decreased cell death when compared to either mock or
pSV controls (p,0.05) (Fig. 7A).
Role of Fas activation in pM-induced JNK activation
Our previous studies with specific MMP-2 downregulation
showed the elevation of TIMP-3, which in turn cleaves Fas-L and
activated Fas/Fas-L apoptotic signaling in lung adenocarcinoma
cells [31]. In corroboration with this report, we observed
remarkably enhanced TIMP-3 levels in pM treatment and the
enhanced TIMP-3 levels were reversed in the combination of
pM+rhMMP-2 (Fig. S2). To assess the possible role of Fas/Fas-L
activation in MMP-2 inhibition induced JNK mediated cell death
in 4910 and 5310 cell lines, rhMMP-2 was supplemented and
whole cell lysates were analyzed for the possible reversal of pM-
induced Fas mediated JNK activation. The expression of FADD,
Fas and Fas-L and phosphorylation of JNK was reduced in the
rhMMP-2 alone when compared to either mock or pSV, which
implies a correlation with the increased cell viability in rhMMP-2
in both 4910 and 5310 cell lines. On the other hand, the rhMMP-
2 supplementation to pM-treated cells counteracted on the pM-
induced FADD, Fas, Fas-L and phospho-JNK expression levels
with no substantial change in the total JNK (Fig. 7B). Subse-
quently, to confirm the role of Fas signaling in the activation of
JNK, we performed a Fas functional blocking experiment with
anti-Fas ab. When the treatment with anti-Fas antibody was
compared to either mock or pSV treatment, there was an evident
decrease in the phosphorylation of JNK with the specific blocking
of Fas activation which showed the Fas-mediated JNK activation
in these glioma xenograft cells (Fig. 7C). In contrast, when Fas
activation was blocked in the pM-treated cells there was a
significant reversal of the elevated JNK phosphorylation, suggest-
ing a role of Fas activation in JNK mediated cell death in MMP-2
downregulated 4910 and 5310 cells.
MMP-2siRNA treatment regressed tumor growth in vivo,
induces apoptosis with decreased phospho-p65 and
elevated expression of phospho-JNK levels
We next proceeded to determine the effect of pM on tumor
growth in vivo. The brain tumor sections were prepared as
described above and the mock, pSV and pM samples were
evaluated histologically for tumor formation and expression levels
Figure 4. Inhibition of TNF-a mediated p65 phosphorylation by reduced interaction of TRADD-TRAF2. A. Whole cell lysates from mock,
pSV- and pM-treated cells were subjected to Western blotting. Blots are representative of at least three independent experiments and blots were
stripped and re-probed with GAPDH to check equal loading of samples. B. The immunoprecipitation experiments were performed by precipitating
TRADD with anti-TRADD antibody or TRAF2 by using anti-TRAF2 antibody using mMACS
TM protein G microbeads and MACS Separation Columns
following manufacturer’s instructions (Miltenyi Biotec, Germany). Immunoprecipitates were electrophoresed and probed with anti-TRADD or anti-
TRAF2 antibodies to confirm the interaction. The non-specific IgG (Nsp-IgG) precipitates were loaded as negative control. C. The 4910 and 5310 cells
were treated with mock, pSV, pM, and the combination treatments were performed by 10 ng/ml TNF-a treatment at the end of 60 h transfection to
either mock or pM. Cells were further incubated for another 12 h and collected at the end of the experiment. Whole cell lysates were subjected
Western blot analysis. The experiment was repeated thrice to verify results. D. The expression levels of phospho-p65 were quantified using ImageJ
1.42 (NIH) and plotted in the bar diagram with mean6SE values obtained from at least three individual repetitions. The significant difference among
different treatments were indicated by ‘‘**’’, at p,0.01.
doi:10.1371/journal.pone.0019341.g004
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tumor development was remarkably regressed in pM-treated mice
(Fig. 8A). We observed a significant reduction in the relative tumor
size at p,0.01 (Fig. 8B). We next evaluated the tumors for the
expression of MMP-2, phospho-p65 and phosho-JNK. In mock
and pSV-treated tumors, we observed high MMP-2 expression
whereas we observed very less MMP-2 expression in pM-treated
tumors (Fig. 8C). Further, immunostaining confirmed the high
phosphorylation levels of p65 in mock and pSV-treated tumor
sections which directly indicates the constitutive NF-kB activity in
these tumor cells, while pM treatment resulted in significant
inhibition of phospho-p65 expression levels (Fig. 8D). Moreover, a
significantly elevated expression of phospho-JNK was observed in
pM-treated tumors when compared to mock and pSV-treated
tumors (Fig. 8E). The results of the TUNEL assay indicate that
pM treatment resulted in induction of apoptosis as evident from
the elevated number of TUNEL-positive cells whereas very few
TUNEL or no TUNEL-positive apoptotic cells were observed in
mock and pSV-treated tumors (p,0.01) (Fig. 8F,G). These in vivo
results corroborate our in vitro results.
Discussion
Extensive endothelial proliferations, robust growth and further
dissemination of tumor cells are the consequences of extracellular
matrix and basement membrane disruption, which is in part
mediated by the action of MMPs [6]. In the present study, we
demonstrate that the transcriptional inactivation of MMP-2
Figure 5. MMP-2 downregulation activated phosphorylation of MAP kinases and had a pro-apoptotic effect via activation of JNK. A.
Whole cell lysates collected at different time points from mock, pSV- and pM-treated cells and were subjected to Western blotting. GAPDH was used
as an internal control. Blots are representative of at least three independent experiments. B. The 4910 and 5310 cells were treated with mock, pSV and
pM for 48 h and further treated with either SP600125 or SB203580 for another 24 h. At the end of 72 h cells were subjected to MTT cell viability assay.
Data are presented as mean6SE and where significant difference among various treatment groups was represented by ‘‘*’’, at p,0.05 and ‘‘**’’, at
p,0.01. C. Cells were collected at different time points (24 h, 48 h and 72 h) after pM transfection, and whole cell lysates were used to determine
SAPK/JNK activity assay by quantitative immunoblotting using the non-radiolabeling method. Membranes were probed with phospho-c-jun (Ser 63).
D. Individual treatments to 4910 and 5310 cells including mock, pSV and pM were carried out for 48 h followed by treatment with either SP600125 or
SB203580 for another 24 h at the end of which cells were harvested. Whole cell lysates were subjected to Western blotting for cleavage of PARP,
caspase-8 and caspase-3 and expression levels of phospho-JNK, JNK, phospho-p38 and p38. Representative blots from at least three independent
experiments were shown.
doi:10.1371/journal.pone.0019341.g005
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through suppression of the NF-kB and activation of JNK.
TNF-a mediates its downstream effects by transducing signals to
different effectors, including IKK, JNK and caspases [10]. It is
noteworthy that IKK activation inhibits caspase-mediated apop-
tosis through the transcription factor NF-kB, whose target genes
includes caspase inhibitors. Several lines of evidence suggest the
existence of negative cross-talk between the NF-kB and the JNK
pathways. Previous studies have demonstrated that, in mouse
embryonic fibroblasts that are deficient of the catalytic subunit
IKKb or p65, the IKK/NF-kB pathway negatively regulates
TNF-a-mediated JNK activation partly through the upregulation
of NF-kB-induced XIAP and gadd45beta/myd118 [10]. Our
studies with TNF-a treatment showed p65 downregulation in
MMP-2siRNA treatments indicating a possible role of MMP-2 in
the regulation TNF-a induced NF-kB activation. RIP is part of the
TNFR1 complex and consists of three domains: death domain, S/
T kinase homology domain, and poorly conserved intermediate
domain where the death domain of RIP facilitates its interaction
with the death domain of CD95 (Fas/APO-1), which is responsible
for apoptotic induction while the intermediate domain is essential
for activation of NF-kB [10,23,33]. In addition, previous
researchers have demonstrated that the death domain of RIP is
sufficient to induce apoptosis, and RIP
2/2 cells were unresponsive
to TNF-a stimulated NF-kB activation. RIP is cleaved into RIPn
(containing the entire kinase domain) and RIPc fragments by the
action of caspase-8, which results in inhibition of TNF-a-induced
NF-kB activation and induces apoptosis probably through
Figure 6. Effect of rhMMP-2 treatment on pM-inhibited NF-kB activity. A. The 4910 and 5310 cells were transfected with mock, pSV and pM
for 48 h and treated with 25 ng/ml rhMMP-2 for another 24 h. Whole cell lysates from mock, pSV, pM, rhMMP-2, pM+rhMMP-2 treatments were
prepared at the end of 72 h experiment and subjected to Western blotting to check the expression levels of MMP-2, and cleavage of PARP, caspase-8
and caspase-3. B. The relative intensity of cleaved caspase-8 and caspase-3 were quantified using ImageJ (NIH) software and plotted in the bar
diagram using mean6SE and significant difference was represented by ‘‘**’’, at p,0.01. C. The expression levels of TNF-a, TRADD, IKKb and, p-IkBa
were checked for the possible reversal and upregulation of IKKb-pIkBa mediated NF-kB pathway. D. The nuclear fractions were checked for phospho-
p65 expression levels in pM+rhMMP-2 combination treatment where HDAC-1 served as nuclear and loading control. E. Electrophoretic mobility shift
assay showing the DNA binding activity of p65. Nuclear extracts at the end of 72 h were prepared from the mock, pSV, pM, rhMMP-2, pM+rhMMP-2
treatments as described above in 4910 and 5310 cells and subjected to EMSA where rhMMP-2+p65a antibody was loaded to check the shift and cold
probe was loaded as negative control.
doi:10.1371/journal.pone.0019341.g006
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current study demonstrating RIP downregulation in MMP-2
depletion suggests a possible role of MMP-2 in the RIP mediated
NF-kB signaling activation.
We observed a significant decrease in the expression levels of
TNF-a, TNFR1, TRADD and TRAF2 and immunoprecipita-
tion experiments revealed inhibited interaction of TRADD-
TRAF2 and along with increased FADD expression levels in
pM-treated 4910 and 5310 glioma xenograft cells. The
decreased TRADD-TRAF2 interaction might lead to the
inhibition of downstream IKKb mediated NF-kB activation.
These results are in corroboration with the previous report on
MMP-2 depletion induced decrease in TRADD in 4910 cells
[32]. FADD was originally identified as an important molecule
for Fas-mediated apoptosis and is an important component in
DISC. DISC, which is at least composed of FADD, caspase 8
and Fas, activates pro-caspase-8, which subsequently activates
effector caspases (e.g., caspase-3) whose activation results in the
induction of apoptosis [34]. Recent reports suggest that FADD
induced apoptosis by modulating different effector molecules,
especially by activating the JNK signaling pathway. Overexpres-
sion of constitutively active JNK or its upstream kinases led to
the induction of apoptosis via caspase activation, whereas
overexpression of dominant negative forms resulted in the
inhibition of apoptosis. Further, JNK is also essential for
activating Fas-mediated death signaling and responsible for
sensitization to apoptosis induced by various drugs [35–37].
FADD phosphorylation, which is a major event in the
chemosensitization to various DNA damaging agents, at the
G2/M check point leads to cell cycle arrest [38]. This
phosphorylation is dependent on JNK signaling, and in turn,
FADD promotes JNK signaling activation [39]. The negative
regulation of TNF-a on Fas-induced apoptosis in tumor cells has
been previously reported in tumor cells [40,41]. Our previous
studies with specific suppression of MMP-2 in lung cancer cells
demonstrated the upregulation of TIMP-3 mediated Fas/Fas-L
apoptotic pathway. In corroboration with these studies, our
current study using MMP-2siRNA shows that the inhibition of
MMP-2 resulted in the elevation of TIMP-3, FADD, Fas, Fas-L
and cleavage of caspase-8, -3 and PARP with simultaneous JNK
activation. The specific functional blocking of Fas activation led
to suppressed pM-induced JNK activation confirming the role of
Fas/Fas-L in the JNK mediated cell death in these glioma
xenograft cells. In our study, both in vitro and in vivo animal
experiments showed JNK activation with pM treatments and
which subsequently led to apoptosis as determined by TUNEL
assay. Reversal experiments with SP600125 for JNK inhibition
corroborate previous reports on JNK-induced cell death through
the activation of caspases. In contrast to JNK, treatments with
SB203580 to inhibit p38 MAPK; our results show that p38
activation did not play a role in pM-induced cell death. On the
other hand, the addition of rhMMP-2 led to enhanced DNA-
binding activity of NF-kB by elevating TRADD expression levels
suggesting a role of MMP-2 in the regulation of NF-kB signaling.
Figure 7. A. Effect of JNK inhibitor (SP600125) and recombinant human MMP-2 (rhMMP-2) treatment on pro-apoptotic effect of MMP-2
downregulation. The number of TUNEL positive cells were scored in randomly selected microscopic fields at the end of various treatments as
described in Materials and Methods. The percentage of apoptotic cells in each treatment was plotted in bar diagrams with mean6SE and significant
difference among various treatment groups was represented by ‘‘*’’, at p,0.05 and ‘‘**’’, at p,0.01 in three individual repetitions. B. Effect of rhMMP-
2 treatment on pM induced FADD, Fas, Fas-L and pJNK expression. The whole cell lysates from different treatments were subjected to Western
blotting. C. Role of Fas in pM induced JNK activation. The Fas/Fas-L function was blocked by using neutralizing antibody against Fas in the individual
treatments. At the end of 60 h transfection, anti-Fas ab (250 ng/ml) was added and cells were further incubated for another 12 h at the end of which
whole cell lysates were prepared and subjected to Western blotting to determine the effect of Fas/Fas-L functional blocking on JNK phosphorylation.
The blots are representative of three individual experiments.
doi:10.1371/journal.pone.0019341.g007
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intracranial tumor development and activated JNK and inhibited
NF-kB nuclear expression levels in in vivo experiments. Here, our
results suggest a model where MMP-2 depletion using MMP-
2siRNA modulates TRADD, TRAF2 interactions, which in
turn, leads to NF-kB inhibition and Fas/Fas-L induced JNK
mediated apoptosis. The present study provides auxillary insights
into the molecular mechanisms underlying siRNA-mediated
MMP-2 downregulation and suggests the potential value of
MMP-2 as a therapeutic target in the treatment of glioma.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria, Peoria, IL,
USA, approved all surgical interventions and post-operative
animal care. The consent was written and approved. The animal
protocol number is 858, dated May 27, 2009, and renewed on
April 27, 2010.
Chemicals and antibodies
We used antibodies specific for MMP-2, TNF-a, TNFR1,
TRADD, RIP, TRAF-2, FADD, p65, and phospho-p65 (Ser536),
phospho-JNK (Ser63), JNK1, phospho-p38 MAPK (Tyr182), p38
MAPK, phospho-c-Jun (Ser73), c-Jun, GAPDH (Santa Cruz
Biotechnology, Santa Cruz, CA), IKKb,I kBa, phospho-IkBa
(Ser32), poly (ADP-Ribose) polymerase, caspases-3 and caspases-8
(Cell Signal Technology, Boston, MA), HRP/Alexa FluorH
conjugated secondary antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA). We also purchased p38 MAPK inhibitor
(SB203580) and JNK inhibitor II (SP600125) (Calbiochem,
Figure 8. Tumorigenicity in vivo in nude mice (nu/nu) brains induced by intracranial injection of 4910 and 5310 cells. The pSV and pM
plasmids were injected into the tumors as described in Materials and Methods while the 16PBS injection served as the mock control treatment. At
the end of the experiment the brains were removed and fixed in 10% phosphate-buffered formaldehyde and the fixed tissue samples were
subsequently embedded in paraffin blocks. A. Hematoxylin and Eosin staining of brain sections displaying the neoplastic growth of tumors after
injections of 4910 and 5310 cells (106 and 606). B. The tumor area from every fifth H&E stained tumor section was calculated with the aid of
microscope attached computer screen and Image Pro Discovery Program software (Media Cybernatics, Inc., Sliver spring, MD). The total tumor
volume is calculated as summed area of tumor on all sections multiplied by width of the sections. The relative brain tumor size was estimated from
mock-pSV and pM treated animals and plotted as mean6SE obtained from a group of 10 animals. The significant difference among different
treatment groups was represented by ‘‘**’’, at p,0.01. C. Immunohistochemical analyses through DAB staining were performed to detect the
expression of MMP-2 in paraformaldehyde embedded tumor sections. Hematoxylin was used for nuclear counter staining and rabbit IgG was used as
a negative control. D, E. Immunohistochemical studies showing the expression of phospho-p65 and phospho-JNK in mock, pSV, pM treated tumor
sections. Hematoxylin was used for nuclear counter-staining and rabbit IgG was used a negative control. F. Examination of in situ cell death by TUNEL
assay of brain tumor cells after treatments. Rabbit IgG was used as a negative control. G. Total number of apoptotic cells was counted in randomly
selected microscopic fields and plotted in bar diagram with mean6SE and significant difference among treatment groups was represented by ‘‘**’’, at
p,0.01.
doi:10.1371/journal.pone.0019341.g008
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body (Millipore, Temecula, CA) and human recombinant-
MMP-2 protein (EMD Biosciences, San Diego, CA) and used in
this study.
Cell culture, Plasmid vector and transient transfection
studies
The 4910 and 5310 human xenograft cell lines (kindly provided
by Dr. David James, University of California at San Francisco),
were generated and maintained in mice and are highly invasive in
the mouse brain [42]. Cells were cultured in RPMI 1640
(Mediatech Inc., Herndon, VA) supplemented with 10% fetal
bovine serum (Invitrogen Corporation, Carlsbad, CA), 50 units/
ml penicillin, and 50 mg/ml streptomycin (Life Technologies, Inc.,
Frederick, MD) in a humidified 5% CO2 chamber maintained at
37uC. The siRNA sequence specific for MMP-2: AACGGA-
CAAAGAGTTGGCAGTATCGATACTGCCAACTCTTTGT-
CCGTT was designed and cloned in CMV promoter driven
mammalian transfection vector, pcDNA3.1(+) (pM) at NheI site
where as pcDNA3.1 (+) vector containing a specific scrambled
sequence for MMP-2 siRNA (pSV): GCACGGAGGTTGCAAA-
GAATAATCGATTATTCTTTGCAACCTCCGTGC, served
as negative control along with mock (16PBS) treatment. Transient
transfection studies were performed using FuGene HD transfec-
tion reagent as per the manufacturer’s instructions (Roche Applied
Science, Indianapolis, IN) as describes previously [30]. Briefly, up
to 70% confluent cells were serum-starved for 6 h after which they
were transfected with mock, pSV and pM, and were harvested at
24 h, 48 h, 72 h and 96 h post-transfection and used for further
molecular analyses. For combination treatments, JNK inhibitor
(SP600125; 10 mM), p38 inhibitor (SB203580; 10 mM) or
recombinant human MMP-2 (rhMMP-2; 25 ng/ml) protein were
supplemented in the medium to cells at 48 h pM post-transfection
and the cells were incubated for another 24 h. For the TNF-a and
anti-Fas functional blocking treatment, at 60 h post-transfection
either TNF-a (10 ng/ml) or anti-Fas (250 ng/ml) were added and
incubated for another 12 h at the end of which cells were
collected.
Gelatin zymography
The gelatinolytic activity of MMP-2 using conditioned media
was measured as described previously [30]. In short, 60 h after
transfection of mock, pSV and pM, 3 mL of serum-free medium
were added, and cells were incubated for another 12 h and the
conditioned media were resolved over 0.1% gelatin-SDS-poly-
acrylamide gels. Gels were washed in 2.5% Triton X-100 to
remove SDS, followed by an overnight incubation at 37uC in Tris-
CaCl2 buffer (pH-7.6) and stained with Coomassie brilliant blue.
The gelatinolytic activity of the protein was visualized through
negative staining as clear sectors of lyses against a dark blue
backdrop.
RNA isolation and Reverse transcriptase polymerase
chain reaction (RT-PCR)
Total RNA from mock, pSV- and pM-treated cells was
extracted at 72 h post-transfection using TRIzol reagent (Invitro-
gen) as per the manufacturer’s instructions. The ImProm-II
Reverse Transcription (Promega Corporation, Madison, WI)
along with 2 mg of total RNA and poly-dT primers were used
for synthesis of cDNA. To determine the RNA transcript levels
from cDNA, PCR was carried out with 1 mL of cDNA using the
following primers: for MMP-2 sense 59-GTGCTGAAGGACA-
CACTAAAGA-39 and antisense 59-CCTACAACTTTGAGAA-
GGATGGCAA-39, and for GAPDH sense 59- GGAGTCAACG-
GATTTGGTCGTAT -39 and antisense 59- GTCTTCACCAC-
CATGGAGAAGGCT -39. The PCR conditions were as follows:
initial denaturation at 95uC for 3 min, followed by 30 cycles
at 95uC for 1 min, 58uC for 30 sec, 72uC for 45 sec, followed
by a final extension at 72uC for 10 min. Amplified PCR products
were visualized in ethidium bromide agarose gels under ultraviolet
light.
Preparation of cytoplasmic and nuclear extract
Cells were treated with mock, pSV, pM, SP600125,
pM+SP600125, rhMMP-2, or pM+rhMMP-2 for 72 h as de-
scribed above, collected and washed twice with ice-cold PBS. The
nuclear and cytoplasmic proteins were prepared using the
Biovision Nuclear/Cytosol Fractionation Kit (Mountain View,
CA) as per manufacturer’s instructions and used in further
analyses [43].
Western blotting, immunoprecipitation and cytokine
antibody array
Cells were harvested at the end of different treatments and lysed
in radioimmunoprecipitation assay (RIPA) buffer containing
protease inhibitors as described previously [31]. For immunopre-
cipitation, quantified whole cell lysates were precipitated with anti-
TRADD antibody using mMACS
TM protein G microbeads and
MACS Separation Columns following manufacturer’s instructions
(Miltenyi Biotec, Germany). Equal amounts of protein fractions or
immunoprecipitates of lysates with indicated antibodies were
resolved over SDS-PAGE and transferred on to PVDF membrane.
Blots were incubated in respective primary antibodies followed by
incubation in HRP-conjugated secondary antibodies and subse-
quently exposed to autoradiography. The Human Cytokine Array
3 kit was used to verify relative levels of cytokines released from
4910 and 5310 cells after pSV and pM treatments using
conditioned media following manufacturer’s instructions (Ray
BiotechH, Norcross, GA) as described previously [44]. Each
cytokine was present in duplicate on the array in the form of dots
and the array was repeated thrice to confirm similar results. The
average signal intensities of both dots for expression analysis of
each cytokine were compared where biotin-conjugated IgG was
used for positive signal. Differential changes in cytokine produc-
tion were calculated by densitometric analysis using ImageJ 1.42
(NIH) software.
Electrophoretic mobility shift assay
Nuclear extracts from mock, pSV, pM, rhMMP-2 and
pM+rhMMP-2 treated cells were analyzed using the electropho-
retic gel shift assay. The anti-p65 (p65a) antibody was added to
check the specificity and cold probe served as a negative control.
The complexes of protein–biotin labeled p65 binding DNA were
resolved on a 5% non-denaturing gel, subsequently transferred
onto N
+ membrane, and subjected to autoradiography as per the
manufacturer’s instructions (Panomics EMSA Kit, Panomic, Inc.
Fremont, CA).
JNK activity assay
A non-radiolabeling quantitative immunoblotting SAPK/JNK
Kinase Assay Kit (Cell Signal Technology, Boston, MA) was used
to perform the JNK activity assay. Cells were treated with mock,
pSV or pM and whole cell lysates were prepared and immobilized,
and c-Jun fusion protein bead slurry was added as described in the
manufacturer’s protocol. The samples were incubated overnight at
4uC and subsequently centrifuged and the pellet was incubated
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The samples were resolved on SDS-PAGE and transferred onto
the PVDF membrane and Western blotting was carried out to
detect phosphorylated c-Jun.
MTT assay
The 4910 and 5310 cells (1610
3/well) were plated in a 96-well
plate and incubated overnight. Treatments of mock, pSV, pM in
combination either SP600125 or SB203580 were carried out for
72 h as described above. Cell viability was determined by MTT
assay as described earlier [41]. Absorbance was read at 590 nm
using a 96-well microplate reader.
Flow cytometry
Cells were transfected with mock, pSV or pM as described
above and were harvested after 72 h and fixed in 70% ethanol for
1 h at 4uC. Subsequently, the cells were stained with propidium
iodide (BioSure, Grass Valley, CA) for 30 min in the dark and
FACS analysis was performed using a Becton-Dickinson FACS
Calibur flow cytometer (BD Biosciences, Heidelberg, Germany).
Results were analyzed with Cell Quest software (BD Biosciences,
Heidelberg, Germany).
In situ terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay
The apoptotic population of mock, pSV- and pM-treated cells
or paraformaldehyde fixed and paraffin embedded mice brain
tumor sections from 4910/5310 xenograft cells was detected using
a TUNEL apoptosis detection kit (Roche Diagnostics, Indianap-
olis, IN) following manufacturer’s protocol. Samples were
incubated in TUNEL reaction mixture containing TdT and
fluorescein-dUTP at 37uC for 1 h where TdT catalyses the
binding of fluorescein-dUTP to free 39OH ends in the nicked
DNA. The cells were visualized for the incorporated fluorescein
under confocal microscope.
Immunocytochemical and immunohistochemical
analyses
Immunocytochemical and immunohistochemical analyses
were performed as described earlier [41]. The transfected 4910
and 5310 cells in chamber slides were fixed in paraformaldehyde
followed by permeabilization in 0.1% Triton-X100. Non-specific
binding was blocked in 1% BSA in PBS, followed by incubation
with anti-MMP-2 and anti-p65 antibodies for 2 h at room
temperature. The cells were washed and incubated with Alexa
FluorH-conjugated secondary antibodies, subsequently mounted.
For nuclear counterstaining, 49-6-diamidino-2-phenylindole
(DAPI) was used. For immunohistochemical analysis, tissue
sections (4–5 mm) were de-paraffinized in xylene, rehydrated in
graded ethanol solutions, permeabilized in 0.1% Triton X-100,
and incubated overnight at 4uC with anti-MMP-2, anti-phospho-
p65 and anti-phospho-JNK antibodies. Slides were washed twice
in PBS and incubated in either Alexa FluorH- or HRP-
conjugated secondary antibodies for 1 h at room temperature
followed by counterstaining with DAPI. For DAB staining, the
HRP-conjugated secondary antibodies incubated sections were
washed and further incubated with DAB (3,39-Diaminobenzi-
dine) solution for 5–10 min while Hematoxylin was used for
nuclear counterstaining, mounted and photographed under a
microscope.
In-vivo experiments
The 4910 and 5310 cells (2610
6 cells/100 mL) were injected
sterotactically into athymic, female, 4–6-week old nu/nu mice
as described previously [30]. After 10 days, the animals were
divided into three sets (n=10) and ALZET osmotic pumps
(model 2004, ALZETH Osmotic Pumps, Cupertino, CA) were
implanted for plasmid delivery (dose: 6 mg/kg body weight).
Animals losing .20% of the body weight or having problems in
feeding and grooming were euthanized. Animals were observed
up to 60 days at the end of which brains were excised and fixed
in 10% buffered formalin, and embedded in paraffin. To
visualize tumor cells and to examine tumor development, the
brain sections were stained with H&E. The tumor area from
every fifth H&E stained tumor section was calculated with the
aid of microscope attached computer screen and Image Pro
Discovery Program software (Media Cybernatics, Inc., Sliver
spring, MD). The total tumor volume is calculated as summed
tumor area on all sections multiplied by width of the sections.
The relative brain tumor size was estimated from mock-pSV
and pM treated animals and plotted as mean6SE obtained from
a group of 10 animals.
Statistical analysis
Data obtained from different treatment groups were analyzed
using one-way ANOVA by Neumann-Keuls method of Sigmastat
3.1. The relative expression or fluorescence intensities were
quantified using ImageJ 1.42 software (NIH, U.S.A.). Data were
represented in the form of mean6SE, which was obtained from at
least three individual repetitions and the significant difference
among different treatment groups was denoted by ‘‘*’’, at p,0.05
and ‘‘**’’, at p,0.01.
Supporting Information
Figure S1 Effect of rhMMP-2 and JNK inhibition by
SP600125 treatment on pM-induced apoptosis. Represen-
tative images show apoptotic cell death by TUNEL assay in
three individual repetitions at the end of 72 h in 4910 and 5310
cells.
(TIF)
Figure S2 Western blotting showing the expression
levels of TIMP-3 in mock, pSV, pM, rhMMP-2,
pM+rhMMP-2 treatments in 4910 and 5310 cells.
(TIF)
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